Prenetics Global Limited (PRE) Income Statement

The trajectory is compelling on headline scale, but the near-flat print in 2025Q3-Q4 followed by a 162.9% jump in 2026Q2 suggests revenue may be driven by episodic contracts or deal timing rather than a smoothly compounding recurring base. Investors should investigate what specifically changed between 2025Q4 and 2026Q2 to determine whether the re-acceleration reflects a durable new vertical or a lumpy event.

The 2024-2025 margin compression (59.0% → 37.2%) followed by recovery to 65.0% suggests mix or cost-of-sales dynamics are shifting materially between quarters, which is unusual for a diagnostics business with largely fixed manufacturing overhead. The recent 64.8-65.0% stability is encouraging, but the historical volatility argues against treating the current margin as structural without further disclosure on product or service mix.

Conventional operating leverage logic would predict that a 700%+ gross profit expansion should have driven operating income toward breakeven by now; instead, the latest operating loss (-$21.9M) is the widest in the dataset. This pattern suggests management is front-loading commercial and corporate spending to capture share ahead of cost absorption, which is defensible strategically but leaves the business structurally dependent on continued top-line acceleration to justify the overhead base.

The SG&A ratio trajectory reveals a business that initially over-indexed on overhead relative to its small revenue base, found efficiency as revenue scaled, then appears to be re-investing aggressively in 2026 — a swing that could indicate an acquisition integration cost or a deliberate expansion push. R&D spending, meanwhile, has declined to under $2M per quarter in the most recent periods, which is unusual for a diagnostics company and raises the question of whether innovation investment is being crowded out by commercialization spend.